A BILL 
To amend the Federal Food, Drug, and Cosmetic Act with 
respect to approval of abbreviated new drug applications. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Reforming Evergreen-
4
ing and Manipulation that Extends Drug Years Act’’ or 
5
the ‘‘REMEDY Act’’. 
6
SEC. 2. AMENDMENTS TO ANDA APPROVAL PROVISION. 
7
(a) IN GENERAL.—Section 505 of the Federal Food, 
8
Drug, and Cosmetic Act (21 U.S.C. 355) is amended— 
9
03:44 Jul 30, 2019
H3812
dlhill on DSKBBY8HB2PROD with BILLS
2 
•HR 3812 IH
(1) in subsection (c)(3)(C), by inserting ‘‘in the 
1
case of a certification with respect to a patent that 
2
claims a drug substance (and not in the case of a 
3
certification with respect to a patent that claims a 
4
drug product or method of use for a drug, except 
5
that, in the case of a patent that claims a drug sub-
6
stance and a drug product or method of use, this 
7
subparagraph shall apply, but only to the extent the 
8
patent claims a drug substance),’’ after ‘‘imme-
9
diately unless,’’; and 
10
(2) in subsection (j)(5)(B)(iii), by inserting ‘‘in 
11
the case of a certification with respect to a patent 
12
that claims a drug substance (and not in the case 
13
of a certification with respect to a patent that claims 
14
a drug product or method of use for a drug, except 
15
that, in the case of a patent that claims a drug sub-
16
stance and a drug product or method of use, this 
17
clause shall apply, but only to the extent the patent 
18
claims a drug substance),’’ after ‘‘immediately un-
19
less,’’. 
20
(b) ORANGE BOOK UPDATES WITH RESPECT TO IN-
21
VALIDATED PATENTS.— 
22
(1) IN GENERAL.—Section 505(j)(7)(A) of the 
23
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
24
03:44 Jul 30, 2019
H3812
dlhill on DSKBBY8HB2PROD with BILLS
3 
•HR 3812 IH
355(j)(7)(A)) is amended by adding at the end the 
1
following: 
2
‘‘(iv) In the case of a listed drug for which the 
3
list under clause (i) includes a patent that claims the 
4
drug or a use for such drug, and where the Under 
5
Secretary of Commerce for Intellectual Property and 
6
Director of the United States Patent and Trade-
7
mark Office has cancelled any claim of the patent 
8
relating to such drug or such use pursuant to a de-
9
termination by the Patent Trial and Appeal Board 
10
in an inter partes review conducted under chapter 
11
31 of title 35, United States Code, or a post-grant 
12
review conducted under chapter 32 of that title, and 
13
any such cancellation, if appealed, has been upheld 
14
upon appeal, the holder of the applicable approved 
15
application shall notify the Secretary of such can-
16
cellation, and the revisions required under clause 
17
(iii) shall include striking the patent from the list 
18
with respect to such drug.’’. 
19
(2) NO EFFECT ON FIRST APPLICANT EXCLU-
20
SIVITY
PERIOD.—Section 
505(j)(5)(B)(iv)(I) 
is 
21
amended by adding at the end the following: ‘‘This 
22
subclause shall apply even if a patent is stricken 
23
from the list under paragraph (7)(A), pursuant to 
24
the second sentence of clause (iii) of such paragraph, 
25
03:44 Jul 30, 2019
H3812
dlhill on DSKBBY8HB2PROD with BILLS
4 
•HR 3812 IH
provided that, at the time that the first applicant 
1
submitted an application under this subsection con-
2
taining a certification described in paragraph 
3
(2)(A)(vii)(IV), the patent that was the subject of 
4
such certification was included in such list with re-
5
spect to the listed drug.’’. 
6
Æ 
03:44 Jul 30, 2019
H3812
dlhill on DSKBBY8HB2PROD with BILLS
